IP Library › Granted Patent US 10,478,415
Granted Patent B2
US 10,478,415 · App. 15/403,982 · Granted Nov 19, 2019

Ketone bodies to protect tissues from damage by ionizing radiation

Inventors: Richard Lewis Veech (Rockville, MD); Kieran Clarke (Oxford, GB)
Assignees: TDELTAS LIMITED; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
A61K31/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,478,415
App. No.
15/403,982
Granted
Nov 19, 2019
Kind
B2
Abstract

Described herein is the surprising discovery that ketone bodies protect cell and tissues from ionizing radiation. Based on this finding, methods of protecting animal tissue and cells from damage caused by radiation exposure are disclosed which include, contacting the tissue with a therapeutically effective amount of an agent including at least one ketone ester, thereby protecting the tissue from radiation damage. Ketone esters can be used to minimize, reduce and/or prevent tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage.

Claims (22)

1. A method of protecting animal tissue from damage caused by radiation exposure, comprising contacting the tissue of a subject in need thereof with a therapeutically effective amount of an agent, wherein the agent is:

wherein n and m are 3; or

wherein n is 3;

thereby protecting the tissue from radiation damage.

2. The method of claim 1 , wherein the method protects a subject exposed to a radioactive substance or ionizing radiation.

3. The method of claim 1 , wherein contacting is performed at least one of before, during or after exposure to radiation.

4. The method of claim 3 , wherein contacting comprises administering to the subject in need thereof the agent within two weeks prior to exposure to radiation, during radiation exposure, and/or within two weeks following radiation exposure.

5. The method of claim 3 , wherein contacting comprises administering to the subject in need thereof the agent within four days prior to radiation exposure, during radiation exposure, and/or within about one day following radiation exposure.

6. The method of claim 1 , wherein the radiation comprises an acute or chronic dose of ionizing or non-ionizing radiation.

7. The method of claim 6 , wherein the ionizing radiation results from nuclear fission or fusion.

8. The method of claim 6 , wherein the ionizing radiation comprises X-rays.

9. The method of claim 6 , wherein the ionizing radiation comprises radionuclides.

10. The method of claim 1 , wherein the method enhances the therapeutic window for radiotherapy in the subject, comprising contacting tissue of the subject with the therapeutically effective amount of the agent including at least one ketone ester prior to the radiotherapy.

11. The method of claim 1 , wherein the radiation exposure comprises diagnostic X-rays, radiation therapy, a CAT-scan, a mammogram, a radionuclide scan, or an interventional radiological procedure under CT or fluoroscopy guidance.

12. The method of claim 1 , wherein the radiation exposure comprises tissue-incorporated radionuclides from ingestion of contaminated food or water, non-medical or unintentional exposure to ionizing radiation from a nuclear weapon, non-medical or unintentional exposure to a radioactive spill, cosmic radiation, and/or space flight-associated radiation expose.

13. The method of claim 1 or claim 10 , wherein the agent is administered topically, buccally, intraocularly, orally, subcutaneously, intramuscularly, intravenously, intraarterially, transdermally, intranasally, rectally, peritoneally, or by inhalation.

14. The method of claim 1 or claim 10 , wherein administering the compound raises the blood ketone body concentration to between 0.1 mM and 20 mM.

15. The method according to claim 13 , wherein administering comprises administering from about 5 grams to about 70 grams of the compound.

16. The method according to claim 13 , wherein administering comprises administering from about 70 milligrams to about 5 grams per kilogram of the subject's body weight.

17. The method according to claim 13 , wherein administering comprises administering from about 1 gram to about 4 grams per kilogram of the subject's body weight.

18. The method according to claim 13 , wherein administering comprises administering 130 grams to about 170 grams per day to the subject.

19. The method of claim 18 , wherein administering comprises administering 150 grams per day to the subject.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2017
From: VEECH, RICHARD LEWIS
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 041543/0007 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2017
From: CLARKE, KIERAN
To: TDELTAS
Reel/Frame 041543/0135 →
Continuity (3)
Continuation 14440634
Provisional Application 61722630 · Nov 5, 2012
Related Publication 20170196827A1 · Jul 13, 2017
Cited By (3)
US 12,377,032 US 12,396,974 US 12,703,842